Méndez-Herrera A, Arias-Toledo E, Sánchez-Alemán M, Olamendi-Portugal ML, Ruiz-Gómez J, Díaz-Ortega JL. [[Antibody prevalence to mumps in children and adolescents at two years of the introduction of the MMR vaccine]].
SALUD PUBLICA DE MEXICO 2018;
60:71-76. [PMID:
29689659 DOI:
10.21149/8138]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 10/06/2017] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVE
To assess the prevalence of mumps antibodies in children and adolescents of Mexico, two years after the introduction of the mumps-containing vaccine MMR.
MATERIALS AND METHODS
Evaluation of IgG antibodies with a commercial kit of indirect ELISA.
RESULTS
2 111 children (1-9 years) and 2484 adolescents (10-19 years) were studied. The overall antibody seroprevalence was 70.6% (95% CI 69.3-71.9), being higher in adolescents (83.0%, 95%CI 81.5-84.5) than in children (56.0%, 95%CI: 53.9-58.11) (OR 3.83, 95%CI 3.34-4.39, p=0.0000000). Children 1 to 2 and 6 to 9 years who were part of the target group of mumps vaccination since 1998, they had higher seroprevalence than the group of 3 to 5 years unvaccinated.
CONCLUSIONS
Seropositivity in children aged 1 to 2 and 6 to 9 years was probably attributable to vaccination during 1998-2000 and in other age groups to natural exposure related to time elapsed in each birth cohort until the study recruitment.
Collapse